Back to Search Start Over

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis.

Authors :
Ellenberger, David
Eichstädt, Kerstin
Flachenecker, Peter
Friede, Tim
Haas, Judith
Kleinschnitz, Christoph
Pöhlau, Dieter
Rienhoff, Otto
Stahmann, Alexander
Zettl, Uwe K
Rommer, Paulus S
Source :
Multiple Sclerosis & Related Disorders; Oct2018, Vol. 25, p173-174, 2p
Publication Year :
2018

Abstract

Highlights • Glucocorticosteroid (GCS) continuous to decrease in Germany. • Natalizumab utilization decreased with the emergence of additional treatment options. • GCS utilization decreases for both RRMS and SPMS. • The generally observed decrease in relapses per year is confirmed with in the data. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
22110348
Volume :
25
Database :
Supplemental Index
Journal :
Multiple Sclerosis & Related Disorders
Publication Type :
Academic Journal
Accession number :
132689567
Full Text :
https://doi.org/10.1016/j.msard.2018.07.040